Common Name : Ciprofloxacin Hydrochloride infusion
Ingredients : Ciprofloxacin hydrochloride. Chemical name: 1-cyclopropyl-6-fluoro-1,4-dihydro-4oxo-7 (1-piperazinyl) -3-quinoline carboxylic acid hydrochloride monohydrate.
Character : This product is a white or slightly yellow freeze-dried block.
Function category
Pharmacology and Toxicology : Pharmacological effects: This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic gram-negative bacteria. It has good antibacterial effects in vitro against the following bacteria: most bacteria in the family Enterobacteriaceae, including Enterobacteriaceae such as Citrobacter, Clostridium, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has antibacterial activity against multidrug-resistant bacteria. Neisseria gonorrhoeae, influenza producing bacteria, and Moraceae, which are resistant to penicillin, all have high antibacterial activity. It has antibacterial effects on most strains of Pseudomonas species such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin sensitive Staphylococcus, but only moderate antibacterial activity against Streptococcus pneumoniae, Streptococcus hemolyticus, and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, and Legionella, as well as antibacterial activity against Mycobacterium tuberculosis and atypical Mycobacterium. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a fungicide that inhibits the synthesis and replication of DNA by acting on the A subunit of bacterial DNA helicase, leading to bacterial death. Toxicological studies: Carcinogenicity and mutagenicity: Eight in vitro mutagenicity tests have been conducted on ciprofloxacin, with two results being positive (rat liver cell DNA repair test and mouse lymphoma cell reverse mutation test). However, in vivo tests such as rat liver cell DNA repair test, micronucleus test (in mice), and dominant lethal test (in mice) were all negative. Long term carcinogenic in vivo experiments have been completed on rats and mice, and after daily oral administration for 2 consecutive years, these animals did not show any carcinogenic or tumorigenic effects of ciprofloxacin. Reproductive toxicity: Reproductive studies have been conducted on rats and mice taking drugs at doses six times the usual daily dose of humans, and it has not been found that ciprofloxacin is harmful to fetuses or causes damage to fertility. Ciprofloxacin produces gastrointestinal disorders when used in rabbits (30 and 100mg/kg orally), leading to weight loss and increased miscarriage in female rabbits. However, no teratogenic effects were observed at both doses. After intravenous administration of 20mg/kg, there was no maternal toxicity, embryonic toxicity, or teratogenic effect. However, sufficient and well controlled studies have not been conducted on pregnant women. For pregnant women, ciprofloxacin should only be used when its potential benefits outweigh the potential risks to the fetus.
Indications : Used for infections caused by sensitive bacteria: 1. Urinary and reproductive system infections, including simple and complex urinary tract infections, bacterial prostatitis, Neisseria gonorrhoeae urethritis or cervicitis (including those caused by enzyme producing strains). 2. Respiratory infections, including acute episodes of bronchial infections caused by sensitive Gram negative bacteria and pulmonary infections. 3. Gastrointestinal infections are caused by Shigella, Salmonella, Enterotoxin producing Escherichia coli, Aeromonas hydrophila, Vibrio parahaemolyticus, etc. 4. Typhoid fev
Audited Supplier 
){kind=link}